Abstract:Luyao Liu, 1 Wang Xiao, 2 Chaojie Zhang, 1 Peizhi Fan, 1 Jie Zeng, 1 Jianing Yi 1 1 Department of Breast and Thyroid Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, People's Republic of China; 2 Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, People's Republic of China Correspondence: Jianing Yi; Jie Zeng, Department of Breast and Thyroid Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, 61 Jiefang West Road, Changsha, Hunan, 410005, People's Republic of China, Tel +8613007436234 ; +8613974837749, Email ; Background: Breast cancer (BC) continues to pose a substantial challenge to global health, necessitating an enhanced understanding of its fundamental mechanisms. Among its various pathological classifications, breast invasive carcinoma (BRCA) is the most prevalent. The role of the transcription factor forkhead box P3 ( FOXP3 ), associated with regulatory T cells, in BRCA's diagnosis and prognosis remains insufficiently explored, despite its recognized importance. Methods: We examined the mRNA expression profile of FOXP3 in BRCA patients, assessing its correlation with disease detection, patient survival, immune checkpoint alterations, and response to anticancer drugs. Results: Our analysis revealed significantly elevated FOXP3 mRNA levels in BRCA patients, with a 95.7% accuracy for BRCA detection based on the area under the curve. High FOXP3 mRNA levels were positively correlated with overall survival and showed significant associations with CTLA4, CD274, PDCD1 , TMB, and immune cell infiltration status. Furthermore, FOXP3 mRNA expression was linked to the efficacy of anticancer drugs and the tumor inflammation signature. Discussion: These findings suggest that FOXP3 serves as a promising biomarker for BRCA, offering valuable insights into its diagnosis and prognosis. The correlation between FOXP3 expression and immune checkpoint alterations, along with its predictive value for treatment response, underscores its potential in guiding therapeutic strategies. Conclusion: FOXP3 stands out as an influential factor in BRCA, highlighting its diagnostic accuracy and prognostic value. Its association with immune responses and treatment efficacy opens new avenues for research and clinical applications, positioning FOXP3 as a vital target for further investigation in BRCA management. Keywords: breast cancer, FOXP3 , regulatory T cells, immune checkpoint alterations, anticancer drugs response, immune cell infiltration BRCA burden is rising rapidly and varies widely from country to country. The incidence and mortality of BRCA in China and South Korea have increased rapidly, whereas those in the United States have declined. 1 In 2020, new cases of BRCA exceeded cases of lung malignancy (2.2 million), reaching 2.26 million and making it the most prevalent cancer in the world. 2 Implementing strategies such as improving healthcare access, increasing health awareness, and employing efficient prevention measures are critical in containing the escalating burden of BRCA. In recent years, BRCA treatment has made great progress through the unremitting efforts of medical and pharmaceutical researchers. 3,4 However, the pathogenesis of BRCA, especially metastatic BRCA, still needs to be unraveled, and the lack of biomarkers for efficient treatment and diagnosis must be addressed. 5,6 The tumor microenvironment (TME) is an intricate system, consisting of stromal, immune, and cancer cells. It has a critical function in the onset and advancement of tumors. Cells linked with the immune system can impact the progression of tumors by altering the TME. Regulatory T cells (Treg cells), which are suppressive cells tied to the immune system, are minimally present in healthy individuals, primarily to prevent the overactivity of immune cells leading to autoimmune diseases. Studies have shown an inverse relationship between the count of Treg cells and tumor prognosis. Their existence is favorable to the expansion, proliferation, encroachment, and metastasis of tumor cells. 7 FOXP3 , a transcription factor specifically associated with CD4+ CD25+ Treg cells, participates in Treg cell differentiation. FOXP3 controls the regulation of gene transcription related to cancer occurrence, invasion, metastasis, differentiation, and angiogenesis. 8–11 Beyond its direct implications, the expression of FOXP3 is regulated by tumor -Abstract Truncated-

Abstract P2-08-16: The cross-talk between nuclear p-ser294-FOXO3a and cytoplasmic MMP-2 in breast cancer survival and treatment response

Abstract 5240: Functional and Therapeutic Significance of ESR1 Gene Fusions in Breast Cancer

Abstract P6-12-03: Proinflammatory and estrogen signaling modulates the chemoresistance and metastasis of breast cancer cells through post-translational modifications of pioneering factor FOXA1

p38-regulated FOXC1 stability is required for colorectal cancer metastasis.

Foxo3a Expression Is A Prognostic Marker In Breast Cancer

Abstract PO5-15-10: Plasticity marker FOXC1 expression accurately predicts efficacy of Adjuvant Tamoxifen + Chemotherapy in reducing all-cause mortality in ER+LN- Breast Cancer: Validation in the SCAN-B Prospective Study (NCT02306096)

Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer

The Potential of FOXP3 in Predicting Survival and Treatment Response in Breast Cancer

The role of transcription factor FOXA1/C2/M1/O3/P1/Q1 in breast cancer

Abstract 3676: A circulating tumor fraction DNA biomarker response stratified by ESR1 mutation status correlates with overall survival in patients with HR+ HER2- metastatic breast cancer

The high protein expression of FOXO3, but not that of FOXO1, is associated with markers of good prognosis

Cyr61, Estrogen Receptor And Foxo3a: The Interplay In Aggressive Breast Carcinomas

FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer

Abstract 2854: Delineating mediators of oncogenesis in FOXR2 -expressing cancers

Abstract P4-02-14: Breast cancer cell/adipocyte crosstalk in obesity hampers the efficacy of tamoxifen

Abstract 5644: The impact of ATF3, JDP2, FOXR2, NAA10, FOXL2, DDX20, and p14ARF on the transactivation of p53

Abstract 1476: OSBPL3 facilitates endoplasmic reticulum stress and stemness in triple negative breast cancer

Abstract P1-13-13: Nuclear envelope Expression of the Oncogene Adipocyte-Associated Methionine Domain Containing Conveys Inferior Prognosis but Increased Sensitivity to Statins and Fluorouracil-Based Therapy

Abstract B011: FOXA1 as a pioneer factor in ERα-DNA interactions and its therapeutic potential in ER+ breast cancer: Insights from ChIP-seq and GWAS in Hispanic populations

The Prognostic Value of Forkhead Box P3 Expression in Operable Breast Cancer: A Large-Scale Meta-Analysis

Abstract P2-06-12: Oncogenic Potential of Trefoil Factor 3 in Initiation of Mammary Carcinoma Through Suppression of P53 Pathway